Pharmaceuticals

China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma

HANGZHOU, China and SHAOXING, China, July 22, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Phase III clinical trial application of ASC40 combined with Bevacizumab for treatment of patients w...

2021-07-22 08:30 2661

Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day

SYDNEY, July 21, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and government in order ...

2021-07-21 22:00 11589

Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy

* Kineta to leverage Samsung Biologics' development and manufacturing expertise to advance KVA12.1 to IND * Samsung Biologics San Francisco R&D center and South Korea headquarters to offer a seamless, end-to-end CDMO service INCHEON, South Korea and SEATTLE, July 20, 2021 /PRNewswire/ -- Sams...

2021-07-20 20:00 1434

Everest Medicines Announces Strategic Collaboration with MediTrust Health Co., Ltd to Develop Novel Payment Solutions for Patients in China

SHANGHAI, July 20, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater C...

2021-07-20 18:42 4807

Juventas Cell Therapy Ltd. Closes Series C Financing to Advance the "Rapid Commercialization and Internationalization" Development Strategy

TIANJIN, China, July 20, 2021 /PRNewswire/ -- Juventas Cell Therapy Ltd., a Chinese biopharmaceutical company announced the close of a $60 million+ Series C financing led by CICC Capital and Oceanpine Capital. The co-investors include Delian Capital and existing investors such as Jiadao Private C...

2021-07-20 10:47 1737

Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcomes

The company employs real-world data and evidence to accelerate research through targeted site and patient recruitment strategies SANTA CLARA, Calif., July 20, 2021 /PRNewswire/ -- Based on its recent analysis of the global clinical research organization (CRO) market,Frost & Sullivan recognizes l...

2021-07-20 01:47 1664

RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib

Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19 Top-line results expected in the coming weeks Opaganib, a novel, dual antiviral and anti-inflammatory investigational COVID-19 pill, demonstratedpotent inhibition of Beta and Gamma variant...

2021-07-19 19:21 17063

Ascentage Pharma Establishes Cooperative R&D Agreement (CRADA) with the National Cancer Institute for Clinical Development of Ascentage Pharma's Drug Compound pelcitoclax

SUZHOU, China, and ROCKVILLE, Md., July 19, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has entered into a Cooperative ...

2021-07-19 18:41 3373

Frontier Biotechnologies' First Long-acting Injectable (Aikening(R)), in a Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients

* The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies * TALENT is the world's first phase III clinical trial of the new long-acting HIV...

2021-07-19 16:23 2773

YishengBio Announces PIKA recombinant COVID-19 vaccine received Phase I clinical trial IND clearance from the UAE

BEIJING, July 19, 2021 /PRNewswire/ -- YishengBio Co., Ltd ("YishengBio") today announced that it has received IND clearance for PIKA recombinant COVID-19 vaccine to conduct Phase I clinical trial from United Arab Emirates Ministry of Health & Prevention. PIKA recombinant COVID-19 vaccine is a PI...

2021-07-19 09:00 2735

Bioelectronica Announces Hypercell™ Expansion for Antibody Discovery, Closing of Oversubscribed Series A Financing, Powering Local Hiring Growth and Expansion of Facilities in Reno

RENO, Nev., July 19, 2021 /PRNewswire/ -- Bioelectronica® Corporation ("Bioelectronica") announced today that it has secured an undisclosed amount in its Series A financing round due to increased interest in Hypercell™, a new hardware tool that can be used to discover new antibodies using compute...

2021-07-19 08:59 2436

Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay

SUZHOU, China, July 16, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced thatParaguay's Ministry of Public Health and Social Welfare (MSPBS) has granted an emerg...

2021-07-16 14:41 36488

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, July 16, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-07-16 08:00 8019

Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function

MELBOURNE, Australia, July 15, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced thatMovement Disorders, the official jou...

2021-07-15 21:52 36660

Atonarp announces innovative new metrology platform Aston, aimed at increasing yield, throughput, and efficiency in semiconductor manufacturing processes

TOKYO, July 15, 2021 /PRNewswire/ -- Atonarp, a leading manufacturer of molecular sensing and diagnostics products for the semiconductor, healthcare, and pharma industries, today announcedAston, an innovative in-situ semiconductor metrology platform with an integrated plasma ionization source. ...

2021-07-15 21:15 3124

Cigna International finds community spirit and duty to society top driver of COVID-19 vaccine uptake

Key research findings: * Vaccine acceptance continues to improve – steady increase in vaccine acceptance, 69% up from 63% in three months * Urgency has increased – those waiting to get a vaccination until more people have had their first one dropped 8% in three months, from 50% to 42% * Vac...

2021-07-15 15:30 45530

Transcenta Announces First Patient Dosed in Global Phase I Clinical Trial of PD-L1/TGF-β Bi-functional Antibody TST005

SUZHOU, China, July 15, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the first US patient has been dosed...

2021-07-15 11:23 2186

Kintor Pharmaceutical Collaborates with Fosun Pharma Development to Commercialise Proxalutamide for Treatment of COVID-19 in India and Africa

SUZHOU, China, July 14, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) today announced that it has entered into a licensing agreement with Shanghai Fosun Pharmaceutical Development Ltd. ("Fosun Pharma Development"), on the commercialisation of proxalutamide for the treatment of CO...

2021-07-15 10:00 34022

Johnson & Johnson Innovation announces extension of innovation partnering office at Monash University in collaboration with Victorian State Government to accelerate the life-sciences hub

- Victorian State Government extends financing of JJIPO@Monash for an additional two years - Extension will further boost Victorian hub for researchers and early-stage companies to connect with industry experts and deliver novel healthcare solutions MELBOURNE, Australia, July 15, 2021 /PRNewswi...

2021-07-15 10:00 1432

Ascentage Pharma and Innovent Biologics Reach Multifaceted Strategic Agreement Totaling US$245 Million Including Commercialization of Olverembatinib (HQP1351) in China, Joint Clinical Development of Lisaftoclax (APG-2575) and Equity Investment

SUZHOU, China, and ROCKVILLE, Md., July 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics (1801.HK, "Innovent"), today an...

2021-07-15 01:43 5527
1 ... 233234235236237238239 ... 314